Posted in Business News Opdivo® (nivolumab) in Combination with CABOMETYX® (cabozantinib) Demonstrates Significant Survival Benefits in Patients with Advanced Renal Cell Carcinoma in Pivotal Phase 3 CheckMate -9ER Trial Editor September 19, 2020 Please leave this field emptyGet every new post delivered right to your inbox. Email * Check your inbox or spam folder to confirm your subscription. Original Source
